Antonio Santidrian, PhD.
Antonio Santidrian, Ph.D., is an accomplished scientist with more than 17 years of experience in anti-cancer translational research. He holds the US-equivalent PharmD title from the University of Barcelona in Barcelona, Spain and a Ph.D. in biomedicine, specializing in anti-cancer therapies from the same University. Dr. Santidrian has focused his scientific career on developing superior cancer drugs, and on biological drugs to improve human health. He has extensive supervisory and management experience and excellent skills in biotech business development, communication, and collaboration.
Prior to Calidi Biotherapeutics, Dr. Santidrian led translational studies at The Scripps Research Institute for several small molecule and biologic drugs to treat Breast Cancer. Those studies led to a patent filing his invention and a technology license to move these treatments into clinical trials. Before that, Dr. Santidrian worked closely on the translational cancer studies for the development of ACADRA to treat Chronic lymphocytic leukemia (CLL). These studies led to a successful Clinical trial phase II.
Dr. Santidrian is the recipient of a fellowship from the Ministry of Science and Education (Spain), Susan G. Komen Breast cancer foundation, and the August Pi I Sunyer Foundation.